title: [Comparative safety study of two commercialised vaccines against canine babesiosis induced by Babesia canis].
abstract: The safety of two vaccines available on the French market against canine babesiosis - Nobivac Piro® (NP) and Pirodog® (P) - have been evaluated. Their local, general and biochemical impacts have been compared in a controlled experimental study. Three groups were used: a control group (T) and two groups vaccinated twice at 21 days interval. All dogs presented moderate local reaction. However, either clinical and biological parameters showed that the NP group presented a significantly more intense reaction at the injection site compared to the P group. No statistical difference has been revealed between the groups P and T evolutions.
authors.affiliation: Ecole Nationale Vétérinaire d'Alfort, Maisons-Alfort, France. ludovic.freyburger@vetagro-sup.fr
authors.forename: L
authors.initials: L
authors.lastname: Freyburger
authors.forename: L
authors.initials: L
authors.lastname: Lemaitre
authors.forename: C
authors.initials: C
authors.lastname: Médaille
authors.forename: F
authors.initials: F
authors.lastname: Oberli
authors.forename: L
authors.initials: L
authors.lastname: Fanchon
authors.forename: P
authors.initials: P
authors.lastname: Bergamo
mesh_terms: D000818:Animals; D001403:Babesia / Q000276:immunology*; D001404:Babesiosis / Q000517:prevention & control / Q000662:veterinary*; D001799:Blood Sedimentation; D001831:Body Temperature; D002097:C-Reactive Protein / Q000032:analysis; D004283:Dog Diseases / Q000517:prevention & control*; D004285:Dogs; D007117:Immunization, Secondary / Q000662:veterinary; D008297:Male; D016052:Protozoan Vaccines / Q000592:standards* / Q000633:toxicity; D012449:Safety
chemical_list: D016052:Protozoan Vaccines; D002097:C-Reactive Protein
references.citation: Vaccine. 2007 Mar 8;25(12):2180-6
references.pmid: 17239495
references.citation: Vet Clin Pathol. 1996;25(4):141-146
references.pmid: 12660962
references.citation: Trends Parasitol. 2005 Apr;21(4):179-84
references.pmid: 15780840
references.citation: Methods. 2006 Sep;40(1):53-9
references.pmid: 16997713
references.citation: Vet Parasitol. 2009 Aug 26;163(4):298-305
references.pmid: 19403239
references.citation: J Vet Med Sci. 2008 Feb;70(2):127-31
references.pmid: 18319571
references.citation: Vaccine. 2007 Nov 1;25(44):7674-86
references.pmid: 17913311
references.citation: Vaccine. 2009 Mar 13;27(12):1787-96
references.pmid: 19208455
references.citation: Vet Parasitol. 2006 May 31;138(1-2):118-25
references.pmid: 16507334
references.citation: Schweiz Arch Tierheilkd. 2007 Oct;149(10):439-48
references.pmid: 17983016
references.citation: Vet Rec. 2003 May 3;152(18):562-4
references.pmid: 12751608
references.citation: Vaccine. 2001 Jul 16;19(28-29):3957-67
references.pmid: 11427271
references.citation: Vet Parasitol. 2001 Sep 12;100(1-2):75-86
references.pmid: 11522408
references.citation: Vet Clin Pathol. 2003;32(2):81-7
references.pmid: 12833223
references.citation: J Immunol. 1991 Jan 15;146(2):431-7
references.pmid: 1987271
references.citation: Exp Anim. 2003 Oct;52(5):387-90
references.pmid: 14625403
references.citation: Vet Clin Pathol. 2005 Jun;34(2):144-7
references.pmid: 15902667
references.citation: Vet Parasitol. 2006 May 31;138(1-2):140-6
references.pmid: 16504401
references.citation: J Parasitol. 1967 Oct;53(5):919-23
references.pmid: 4964860